Synergy of Body Composition, Exercise Oncology and Pharmacokinetics: A Narrative Review in Personalizing Paclitaxel Treatment for Breast Cancer
Authors:
- Nele AdriaenssensNele Adriaenssens
- Stephanie C.M. WuytsSWStephanie C.M. Wuyts
- Stephane SteurbautSSStephane Steurbaut
- Pieter-Jan De SutterPSPieter-Jan De Sutter
- An VermeulenAVAn Vermeulen
- Amy de Haar-HollemanAHAmy de Haar-Holleman
- David BeckwéeDBDavid Beckwée
- Steven ProvynSPSteven Provyn
- Sofie Vande CasteeleSCSofie Vande Casteele
- Jinyu ZhouJZJinyu Zhou
- Katrien LanckmansKLKatrien Lanckmans
- Jan Van BocxlaerJBJan Van Bocxlaer
Preprint
- 4 March 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Paclitaxel is a widely used type of chemotherapy for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing literature on body composition, chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.Keywords
All Related Versions
- Version 1, 2025-03-04, Preprints
- Published version: Cancers, 17 (8).
This publication has 109 references indexed in Scilit:
- Clinical and Molecular Perspectives on Inflammation‐Mediated Regulation of Drug Metabolism and TransportClinical Pharmacology & Therapeutics, 2021
- Effects of exercise dose and type during breast cancer chemotherapy on longer‐term patient‐reported outcomes and health‐related fitness: A randomized controlled trialInternational Journal of Cancer, 2019
- Breast Cancer TreatmentJAMA, 2019
- Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatmentsCancer Chemotherapy and Pharmacology, 2018
- Posttreatment trajectories of physical activity in breast cancer survivorsCancer, 2017
- Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimensCancer Medicine, 2016
- A framework for prescription in exercise‐oncology researchJournal of Cachexia, Sarcopenia and Muscle, 2015
- Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapySupportive Care in Cancer, 2014
- Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patientsBreast Cancer Research and Treatment, 2014
- An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicityCancer Chemotherapy and Pharmacology, 2010